Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11736882,Cmax,"Bile acids decreased the Cmax (ng ml(-1)) [control 10.9 +/- 5.8 (mean+/- s.d.), UDCA 5.0 +/- 4.7 (95% confidence interval for difference; 3.9, 7.8, P = 0.0006), CDCA (600 mg) 5.0 +/- 3.9 (2.6, 9.2, P = 0.0059)] and AUC (ng ml(-1) h) [(control; 60 +/- 36, UDCA 15 +/- 13 (20, 73, P = 0.0064), CDCA (600 mg) 19 +/- 19 (21, 63, P = 0.0038)] of nitrendipine, while elimination half-life remained unchanged.",Effect of bile acids on absorption of nitrendipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736882/),[ng] / [ml],10.9,8924,DB01586,Ursodeoxycholic acid
,11736882,Cmax,"Bile acids decreased the Cmax (ng ml(-1)) [control 10.9 +/- 5.8 (mean+/- s.d.), UDCA 5.0 +/- 4.7 (95% confidence interval for difference; 3.9, 7.8, P = 0.0006), CDCA (600 mg) 5.0 +/- 3.9 (2.6, 9.2, P = 0.0059)] and AUC (ng ml(-1) h) [(control; 60 +/- 36, UDCA 15 +/- 13 (20, 73, P = 0.0064), CDCA (600 mg) 19 +/- 19 (21, 63, P = 0.0038)] of nitrendipine, while elimination half-life remained unchanged.",Effect of bile acids on absorption of nitrendipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736882/),[ng] / [ml],5.0,8925,DB01586,Ursodeoxycholic acid
,11736882,Cmax,"Bile acids decreased the Cmax (ng ml(-1)) [control 10.9 +/- 5.8 (mean+/- s.d.), UDCA 5.0 +/- 4.7 (95% confidence interval for difference; 3.9, 7.8, P = 0.0006), CDCA (600 mg) 5.0 +/- 3.9 (2.6, 9.2, P = 0.0059)] and AUC (ng ml(-1) h) [(control; 60 +/- 36, UDCA 15 +/- 13 (20, 73, P = 0.0064), CDCA (600 mg) 19 +/- 19 (21, 63, P = 0.0038)] of nitrendipine, while elimination half-life remained unchanged.",Effect of bile acids on absorption of nitrendipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736882/),[ng] / [ml],5.0,8926,DB01586,Ursodeoxycholic acid
,11736882,AUC,"Bile acids decreased the Cmax (ng ml(-1)) [control 10.9 +/- 5.8 (mean+/- s.d.), UDCA 5.0 +/- 4.7 (95% confidence interval for difference; 3.9, 7.8, P = 0.0006), CDCA (600 mg) 5.0 +/- 3.9 (2.6, 9.2, P = 0.0059)] and AUC (ng ml(-1) h) [(control; 60 +/- 36, UDCA 15 +/- 13 (20, 73, P = 0.0064), CDCA (600 mg) 19 +/- 19 (21, 63, P = 0.0038)] of nitrendipine, while elimination half-life remained unchanged.",Effect of bile acids on absorption of nitrendipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736882/),[h·ng] / [ml],60,8927,DB01586,Ursodeoxycholic acid
,11736882,AUC,"Bile acids decreased the Cmax (ng ml(-1)) [control 10.9 +/- 5.8 (mean+/- s.d.), UDCA 5.0 +/- 4.7 (95% confidence interval for difference; 3.9, 7.8, P = 0.0006), CDCA (600 mg) 5.0 +/- 3.9 (2.6, 9.2, P = 0.0059)] and AUC (ng ml(-1) h) [(control; 60 +/- 36, UDCA 15 +/- 13 (20, 73, P = 0.0064), CDCA (600 mg) 19 +/- 19 (21, 63, P = 0.0038)] of nitrendipine, while elimination half-life remained unchanged.",Effect of bile acids on absorption of nitrendipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736882/),[h·ng] / [ml],15,8928,DB01586,Ursodeoxycholic acid
,11736882,AUC,"Bile acids decreased the Cmax (ng ml(-1)) [control 10.9 +/- 5.8 (mean+/- s.d.), UDCA 5.0 +/- 4.7 (95% confidence interval for difference; 3.9, 7.8, P = 0.0006), CDCA (600 mg) 5.0 +/- 3.9 (2.6, 9.2, P = 0.0059)] and AUC (ng ml(-1) h) [(control; 60 +/- 36, UDCA 15 +/- 13 (20, 73, P = 0.0064), CDCA (600 mg) 19 +/- 19 (21, 63, P = 0.0038)] of nitrendipine, while elimination half-life remained unchanged.",Effect of bile acids on absorption of nitrendipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736882/),[h·ng] / [ml],19,8929,DB01586,Ursodeoxycholic acid
,15689031,flow rate,"The chromatographic separation was achieved within seven minutes by an isocratic mobile phase containing 1.0 mM ammonium acetate and Acetonitrile (65:35, v/v), flowing through XTerra MS C18, 100 x 2.1, 3.5 microm analytical column, at a flow rate of 0.2 ml/min.",Validation of LC/MS electrospray ionisation method for the estimation of ursodiol in human plasma and its application in bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15689031/),[ml] / [min],0.2,9260,DB01586,Ursodeoxycholic acid
,15689031,m/z,"Ion signals were measured in negative mode for Ursodiol and internal standard at m/z 391.3 and 278.1, respectively.",Validation of LC/MS electrospray ionisation method for the estimation of ursodiol in human plasma and its application in bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15689031/),,391.3,9261,DB01586,Ursodeoxycholic acid
,15689031,m/z,"Ion signals were measured in negative mode for Ursodiol and internal standard at m/z 391.3 and 278.1, respectively.",Validation of LC/MS electrospray ionisation method for the estimation of ursodiol in human plasma and its application in bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15689031/),,278.1,9262,DB01586,Ursodeoxycholic acid
more,15689031,absolute recovery,The absolute recovery was more than 54.90% for Ursodiol and 76.51% for internal standard.,Validation of LC/MS electrospray ionisation method for the estimation of ursodiol in human plasma and its application in bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15689031/),%,54.90,9263,DB01586,Ursodeoxycholic acid
,15689031,absolute recovery,The absolute recovery was more than 54.90% for Ursodiol and 76.51% for internal standard.,Validation of LC/MS electrospray ionisation method for the estimation of ursodiol in human plasma and its application in bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15689031/),%,76.51,9264,DB01586,Ursodeoxycholic acid
,14643509,absolute recovery,"The absolute recovery for UDCA, GDCA, TDCA and the internal standard was 87.3, 83.7, 79.5 and 95.8%, respectively.",High-performance liquid chromatographic mass spectrometric method for the determination of ursodeoxycholic acid and its glycine and taurine conjugates in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14643509/),%,87.3,35169,DB01586,Ursodeoxycholic acid
,14643509,absolute recovery,"The absolute recovery for UDCA, GDCA, TDCA and the internal standard was 87.3, 83.7, 79.5 and 95.8%, respectively.",High-performance liquid chromatographic mass spectrometric method for the determination of ursodeoxycholic acid and its glycine and taurine conjugates in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14643509/),%,83.7,35170,DB01586,Ursodeoxycholic acid
,14643509,absolute recovery,"The absolute recovery for UDCA, GDCA, TDCA and the internal standard was 87.3, 83.7, 79.5 and 95.8%, respectively.",High-performance liquid chromatographic mass spectrometric method for the determination of ursodeoxycholic acid and its glycine and taurine conjugates in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14643509/),%,79.5,35171,DB01586,Ursodeoxycholic acid
,14643509,absolute recovery,"The absolute recovery for UDCA, GDCA, TDCA and the internal standard was 87.3, 83.7, 79.5 and 95.8%, respectively.",High-performance liquid chromatographic mass spectrometric method for the determination of ursodeoxycholic acid and its glycine and taurine conjugates in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14643509/),%,95.8,35172,DB01586,Ursodeoxycholic acid
,15771757,percentage biliary,"The mean percentage biliary ursodeoxycholic acid enrichment after administration of the suspension was not significantly different from that obtained with capsules (44.2 +/- 11.7% vs. 46.9 +/- 10.2%, respectively).",Bioequivalence of a new liquid formulation of ursodeoxycholic acid (Ursofalk suspension) and Ursofalk capsules measured by plasma pharmacokinetics and biliary enrichment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15771757/),%,44.2,39757,DB01586,Ursodeoxycholic acid
,15771757,percentage biliary,"The mean percentage biliary ursodeoxycholic acid enrichment after administration of the suspension was not significantly different from that obtained with capsules (44.2 +/- 11.7% vs. 46.9 +/- 10.2%, respectively).",Bioequivalence of a new liquid formulation of ursodeoxycholic acid (Ursofalk suspension) and Ursofalk capsules measured by plasma pharmacokinetics and biliary enrichment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15771757/),%,46.9,39758,DB01586,Ursodeoxycholic acid
,6831994,Area under the curve (AUC),"Area under the curve (AUC) after UDCA load was significantly reduced (25.24 +/- 9.54) in CF patients, as compared to controls (52.98 +/- 5.87 mean values +/- SD percent dose/liter X hr X kg body weight, P less than 0.001).",Evaluation of an oral ursodeoxycholic acid load in the assessment of bile acid malabsorption in cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6831994/),,25.24,45128,DB01586,Ursodeoxycholic acid
,6831994,Area under the curve (AUC),"Area under the curve (AUC) after UDCA load was significantly reduced (25.24 +/- 9.54) in CF patients, as compared to controls (52.98 +/- 5.87 mean values +/- SD percent dose/liter X hr X kg body weight, P less than 0.001).",Evaluation of an oral ursodeoxycholic acid load in the assessment of bile acid malabsorption in cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6831994/),[%·dose] / [h·kg·l],52.98,45129,DB01586,Ursodeoxycholic acid
,6831994,Total fecal BA,"Total fecal BA were increased in CF patients (7.84 +/- 5.57 mg/kg/day) as compared to control values (2.7 +/- 1.1 mean +/- SD, P less than 00.5); they were inversely correlated with AUC values (r = 0.48) but not with steatorrhea (r = 0.32).",Evaluation of an oral ursodeoxycholic acid load in the assessment of bile acid malabsorption in cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6831994/),[mg] / [d·kg],7.84,45130,DB01586,Ursodeoxycholic acid
,6831994,Total fecal BA,"Total fecal BA were increased in CF patients (7.84 +/- 5.57 mg/kg/day) as compared to control values (2.7 +/- 1.1 mean +/- SD, P less than 00.5); they were inversely correlated with AUC values (r = 0.48) but not with steatorrhea (r = 0.32).",Evaluation of an oral ursodeoxycholic acid load in the assessment of bile acid malabsorption in cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6831994/),,2.7,45131,DB01586,Ursodeoxycholic acid
,32052462,maximum concentration,Noncompartmental pharmacokinetic analysis resulted in (mean ± standard deviation) a maximum concentration of 8749 ± 2840 ng/mL and half-life of 2.1 ± 0.71 hr.,"Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease-A Pilot Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32052462/),[ng] / [ml],8749,53738,DB01586,Ursodeoxycholic acid
,32052462,half-life,Noncompartmental pharmacokinetic analysis resulted in (mean ± standard deviation) a maximum concentration of 8749 ± 2840 ng/mL and half-life of 2.1 ± 0.71 hr.,"Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease-A Pilot Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32052462/),h,2.1,53739,DB01586,Ursodeoxycholic acid
,18446498,X(1,"Multiple linear regression analysis for process optimization revealed that the acceptable UDCA-PLC was obtained wherein the optimal values of X(1), X(2) and X(3) were 3, 60 degrees C and 3 h, respectively.","Process optimization, characterization and pharmacokinetic evaluation in rats of ursodeoxycholic acid-phospholipid complex. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18446498/),c·degrees,3,64797,DB01586,Ursodeoxycholic acid
,18446498,X(2),"Multiple linear regression analysis for process optimization revealed that the acceptable UDCA-PLC was obtained wherein the optimal values of X(1), X(2) and X(3) were 3, 60 degrees C and 3 h, respectively.","Process optimization, characterization and pharmacokinetic evaluation in rats of ursodeoxycholic acid-phospholipid complex. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18446498/),c·degrees,60,64798,DB01586,Ursodeoxycholic acid
,18446498,X(2),"Multiple linear regression analysis for process optimization revealed that the acceptable UDCA-PLC was obtained wherein the optimal values of X(1), X(2) and X(3) were 3, 60 degrees C and 3 h, respectively.","Process optimization, characterization and pharmacokinetic evaluation in rats of ursodeoxycholic acid-phospholipid complex. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18446498/),h,3,64799,DB01586,Ursodeoxycholic acid
,18446498,X(3),"Multiple linear regression analysis for process optimization revealed that the acceptable UDCA-PLC was obtained wherein the optimal values of X(1), X(2) and X(3) were 3, 60 degrees C and 3 h, respectively.","Process optimization, characterization and pharmacokinetic evaluation in rats of ursodeoxycholic acid-phospholipid complex. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18446498/),c·degrees,60,64800,DB01586,Ursodeoxycholic acid
,18446498,X(3),"Multiple linear regression analysis for process optimization revealed that the acceptable UDCA-PLC was obtained wherein the optimal values of X(1), X(2) and X(3) were 3, 60 degrees C and 3 h, respectively.","Process optimization, characterization and pharmacokinetic evaluation in rats of ursodeoxycholic acid-phospholipid complex. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18446498/),h,3,64801,DB01586,Ursodeoxycholic acid
,18446498,T(max),"But pharmacokinetic parameters of the complex in rats were T(max) 1.6 h, C(max) 0.1346 microg/ml, AUC(0-infinity) 11.437 microg x h/ml, respectively.","Process optimization, characterization and pharmacokinetic evaluation in rats of ursodeoxycholic acid-phospholipid complex. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18446498/),h,1.6,64802,DB01586,Ursodeoxycholic acid
,18446498,C(max),"But pharmacokinetic parameters of the complex in rats were T(max) 1.6 h, C(max) 0.1346 microg/ml, AUC(0-infinity) 11.437 microg x h/ml, respectively.","Process optimization, characterization and pharmacokinetic evaluation in rats of ursodeoxycholic acid-phospholipid complex. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18446498/),[μg] / [ml],0.1346,64803,DB01586,Ursodeoxycholic acid
,18446498,AUC(0-infinity),"But pharmacokinetic parameters of the complex in rats were T(max) 1.6 h, C(max) 0.1346 microg/ml, AUC(0-infinity) 11.437 microg x h/ml, respectively.","Process optimization, characterization and pharmacokinetic evaluation in rats of ursodeoxycholic acid-phospholipid complex. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18446498/),[h·μg] / [ml],11.437,64804,DB01586,Ursodeoxycholic acid
,8803529,AUC,"There was no significant effect of ursodiol on CsA absorption: AUC was 5011 vs 5486 ng.h.ml-1, Cmax was 832 vs 871 ng.",A single dose of ursodiol does not affect cyclosporine absorption in liver transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803529/),[h·ng] / [ml],5011,72733,DB01586,Ursodeoxycholic acid
,8803529,AUC,"There was no significant effect of ursodiol on CsA absorption: AUC was 5011 vs 5486 ng.h.ml-1, Cmax was 832 vs 871 ng.",A single dose of ursodiol does not affect cyclosporine absorption in liver transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803529/),[h·ng] / [ml],5486,72734,DB01586,Ursodeoxycholic acid
,8803529,Cmax,"There was no significant effect of ursodiol on CsA absorption: AUC was 5011 vs 5486 ng.h.ml-1, Cmax was 832 vs 871 ng.",A single dose of ursodiol does not affect cyclosporine absorption in liver transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803529/),ng,832,72735,DB01586,Ursodeoxycholic acid
,8803529,Cmax,"There was no significant effect of ursodiol on CsA absorption: AUC was 5011 vs 5486 ng.h.ml-1, Cmax was 832 vs 871 ng.",A single dose of ursodiol does not affect cyclosporine absorption in liver transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803529/),ng,871,72736,DB01586,Ursodeoxycholic acid
,8803529,tmax,"ml-1 and tmax was 2 vs 2 h, after ursodiol and placebo, respectively.",A single dose of ursodiol does not affect cyclosporine absorption in liver transplant patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803529/),h,2,72737,DB01586,Ursodeoxycholic acid
,18443034,area under the curve (AUC)(0-72),Intake of UDCA led to a significant increase in rosuvastatin area under the curve (AUC)(0-72) from 128.5 ng/ml.h to 182.1 ng/ml.h(P = 0.008) compared with the control group.,Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18443034/),[ng] / [h·ml],128.5,76593,DB01586,Ursodeoxycholic acid
,18443034,area under the curve (AUC)(0-72),Intake of UDCA led to a significant increase in rosuvastatin area under the curve (AUC)(0-72) from 128.5 ng/ml.h to 182.1 ng/ml.h(P = 0.008) compared with the control group.,Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18443034/),[ng] / [h·ml],182.1,76594,DB01586,Ursodeoxycholic acid
,18443034,oral clearance,The oral clearance decreased from 155.2 l/h with placebo to 109.8 l/h with UDCA.,Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18443034/),[l] / [h],155.2,76595,DB01586,Ursodeoxycholic acid
,18443034,oral clearance,The oral clearance decreased from 155.2 l/h with placebo to 109.8 l/h with UDCA.,Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18443034/),[l] / [h],109.8,76596,DB01586,Ursodeoxycholic acid
,16678547,area under the plasma concentration-time curve from 0 to 4 hours,"In humans UDCA significantly decreased the extent of digoxin absorption from 0.77 to 0.70 and the oral d3-digoxin area under the plasma concentration-time curve from 0 to 4 hours from 6.4 +/- 1.7 ng.h.mL(-1) to 5.3 +/- 1.5 ng.h.mL(-1) (P = .01 and P = .05, respectively).",Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678547/),[h·ng] / [ml],6.4,99396,DB01586,Ursodeoxycholic acid
,16678547,area under the plasma concentration-time curve from 0 to 4 hours,"In humans UDCA significantly decreased the extent of digoxin absorption from 0.77 to 0.70 and the oral d3-digoxin area under the plasma concentration-time curve from 0 to 4 hours from 6.4 +/- 1.7 ng.h.mL(-1) to 5.3 +/- 1.5 ng.h.mL(-1) (P = .01 and P = .05, respectively).",Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678547/),[h·ng] / [ml],5.3,99397,DB01586,Ursodeoxycholic acid
,10813547,bioavailability,"Although the drug/polymer system improved the in-vitro dissolution rate of ursodeoxycholic acid in simulated intestinal fluid, statistical evaluation of the area under the plasma concentration curves indicated no significant difference in the extent of bioavailability between the two formulations (14.93+/-4.43 vs 14.95+/-5.79 microM h; P > 0.2).",Enhancement of ursodeoxycholic acid bioavailability by cross-linked sodium carboxymethyl cellulose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10813547/),h·μM,14.93,99728,DB01586,Ursodeoxycholic acid
,10813547,bioavailability,"Although the drug/polymer system improved the in-vitro dissolution rate of ursodeoxycholic acid in simulated intestinal fluid, statistical evaluation of the area under the plasma concentration curves indicated no significant difference in the extent of bioavailability between the two formulations (14.93+/-4.43 vs 14.95+/-5.79 microM h; P > 0.2).",Enhancement of ursodeoxycholic acid bioavailability by cross-linked sodium carboxymethyl cellulose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10813547/),h·μM,14.95,99729,DB01586,Ursodeoxycholic acid
,10813547,area under the plasma concentration curve,"However, following the administration of the ursodeoxycholic acid/cross-linked sodium carboxymethyl cellulose system with an enteric-coated capsule, the mean area under the plasma concentration curve (27.60+/-10.11 microM h) was significantly higher than that obtained after treatment with the commercially available ursodeoxycholic acid capsule (16.24+/-8-38 microM h; P < 0.05).",Enhancement of ursodeoxycholic acid bioavailability by cross-linked sodium carboxymethyl cellulose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10813547/),h·μM,27.60,99730,DB01586,Ursodeoxycholic acid
,10813547,area under the plasma concentration curve,"However, following the administration of the ursodeoxycholic acid/cross-linked sodium carboxymethyl cellulose system with an enteric-coated capsule, the mean area under the plasma concentration curve (27.60+/-10.11 microM h) was significantly higher than that obtained after treatment with the commercially available ursodeoxycholic acid capsule (16.24+/-8-38 microM h; P < 0.05).",Enhancement of ursodeoxycholic acid bioavailability by cross-linked sodium carboxymethyl cellulose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10813547/),h·μM,16.24,99731,DB01586,Ursodeoxycholic acid
,21802143,Drug Interaction Probability Score,"The calculated Drug Interaction Probability Score between TAC and LAN was 6, indicating a probable interaction.",Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21802143/),,6,101788,DB01586,Ursodeoxycholic acid
,18612911,T(max),"Pharmacokinetic parameters of UDCA tablet and the PLC in rats were T(max) 1.9144 and 1.5610 h, C(max) 0.0576 and 0.1346 microg/mL, and AUC(0-infinity) 4.736 and 11.437 microg h/mL, respectively.","Preparation, characterization, and bioavailability of ursodeoxycholic acid-phospholipid complex in vivo. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18612911/),h,1.9144,105836,DB01586,Ursodeoxycholic acid
,18612911,T(max),"Pharmacokinetic parameters of UDCA tablet and the PLC in rats were T(max) 1.9144 and 1.5610 h, C(max) 0.0576 and 0.1346 microg/mL, and AUC(0-infinity) 4.736 and 11.437 microg h/mL, respectively.","Preparation, characterization, and bioavailability of ursodeoxycholic acid-phospholipid complex in vivo. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18612911/),h,1.5610,105837,DB01586,Ursodeoxycholic acid
,18612911,C(max),"Pharmacokinetic parameters of UDCA tablet and the PLC in rats were T(max) 1.9144 and 1.5610 h, C(max) 0.0576 and 0.1346 microg/mL, and AUC(0-infinity) 4.736 and 11.437 microg h/mL, respectively.","Preparation, characterization, and bioavailability of ursodeoxycholic acid-phospholipid complex in vivo. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18612911/),[μg] / [ml],0.0576,105838,DB01586,Ursodeoxycholic acid
,18612911,C(max),"Pharmacokinetic parameters of UDCA tablet and the PLC in rats were T(max) 1.9144 and 1.5610 h, C(max) 0.0576 and 0.1346 microg/mL, and AUC(0-infinity) 4.736 and 11.437 microg h/mL, respectively.","Preparation, characterization, and bioavailability of ursodeoxycholic acid-phospholipid complex in vivo. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18612911/),[μg] / [ml],0.1346,105839,DB01586,Ursodeoxycholic acid
,18612911,AUC(0-infinity),"Pharmacokinetic parameters of UDCA tablet and the PLC in rats were T(max) 1.9144 and 1.5610 h, C(max) 0.0576 and 0.1346 microg/mL, and AUC(0-infinity) 4.736 and 11.437 microg h/mL, respectively.","Preparation, characterization, and bioavailability of ursodeoxycholic acid-phospholipid complex in vivo. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18612911/),[h·μg] / [ml],4.736,105840,DB01586,Ursodeoxycholic acid
,18612911,AUC(0-infinity),"Pharmacokinetic parameters of UDCA tablet and the PLC in rats were T(max) 1.9144 and 1.5610 h, C(max) 0.0576 and 0.1346 microg/mL, and AUC(0-infinity) 4.736 and 11.437 microg h/mL, respectively.","Preparation, characterization, and bioavailability of ursodeoxycholic acid-phospholipid complex in vivo. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18612911/),[h·μg] / [ml],11.437,105841,DB01586,Ursodeoxycholic acid
,7284427,t 1/2,"The plasma clearance in control and treated animals after intravenous injection of [14C]UDCA (2 microCi. 20 microgram) followed an identical biphasic exponential curve with t 1/2 of 2 and 30 min, respectively.",Pharmacokinetics and metabolism of [14C]ursodeoxycholic acid in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7284427/),min,2,125050,DB01586,Ursodeoxycholic acid
,7284427,t 1/2,"The plasma clearance in control and treated animals after intravenous injection of [14C]UDCA (2 microCi. 20 microgram) followed an identical biphasic exponential curve with t 1/2 of 2 and 30 min, respectively.",Pharmacokinetics and metabolism of [14C]ursodeoxycholic acid in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7284427/),min,30,125051,DB01586,Ursodeoxycholic acid
,7284427,recovery of,"Biliary excretion kinetics were dependent on the treatment; after 10 min of injection, the recovery of radioactivity in bile was 29.8, 19 and 10.9% in group B, A and control, respectively.",Pharmacokinetics and metabolism of [14C]ursodeoxycholic acid in the rat. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7284427/),%,29.8,125052,DB01586,Ursodeoxycholic acid
,7284427,recovery of,"Biliary excretion kinetics were dependent on the treatment; after 10 min of injection, the recovery of radioactivity in bile was 29.8, 19 and 10.9% in group B, A and control, respectively.",Pharmacokinetics and metabolism of [14C]ursodeoxycholic acid in the rat. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7284427/),%,19,125053,DB01586,Ursodeoxycholic acid
,7284427,recovery of,"Biliary excretion kinetics were dependent on the treatment; after 10 min of injection, the recovery of radioactivity in bile was 29.8, 19 and 10.9% in group B, A and control, respectively.",Pharmacokinetics and metabolism of [14C]ursodeoxycholic acid in the rat. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7284427/),%,10.9,125054,DB01586,Ursodeoxycholic acid
,24135887,area under concentration-time curve,"Compared with control rats, the mean area under concentration-time curve of baicalin was reduced from 13.25 ± 0.24 mg/L h to 7.62 ± 0.15 mg/L h and 4.97 ± 0.21 mg/L h, and the C(max) value was decreased from 1.31 ± 0.03 mg/L to 0.62 ± 0.05 mg/L and 0.36 ± 0.04 mg/L in rats pretreated with ursodeoxycholic acid at doses of 75 mg/kg and 150 mg/kg, respectively, for six consecutive days.",Ursodeoxycholic acid pretreatment reduces oral bioavailability of the multiple drug resistance-associated protein 2 substrate baicalin in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24135887/),[mg] / [h·l],13.25,129658,DB01586,Ursodeoxycholic acid
,24135887,area under concentration-time curve,"Compared with control rats, the mean area under concentration-time curve of baicalin was reduced from 13.25 ± 0.24 mg/L h to 7.62 ± 0.15 mg/L h and 4.97 ± 0.21 mg/L h, and the C(max) value was decreased from 1.31 ± 0.03 mg/L to 0.62 ± 0.05 mg/L and 0.36 ± 0.04 mg/L in rats pretreated with ursodeoxycholic acid at doses of 75 mg/kg and 150 mg/kg, respectively, for six consecutive days.",Ursodeoxycholic acid pretreatment reduces oral bioavailability of the multiple drug resistance-associated protein 2 substrate baicalin in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24135887/),[mg] / [h·l],7.62,129659,DB01586,Ursodeoxycholic acid
,24135887,area under concentration-time curve,"Compared with control rats, the mean area under concentration-time curve of baicalin was reduced from 13.25 ± 0.24 mg/L h to 7.62 ± 0.15 mg/L h and 4.97 ± 0.21 mg/L h, and the C(max) value was decreased from 1.31 ± 0.03 mg/L to 0.62 ± 0.05 mg/L and 0.36 ± 0.04 mg/L in rats pretreated with ursodeoxycholic acid at doses of 75 mg/kg and 150 mg/kg, respectively, for six consecutive days.",Ursodeoxycholic acid pretreatment reduces oral bioavailability of the multiple drug resistance-associated protein 2 substrate baicalin in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24135887/),[mg] / [h·l],4.97,129660,DB01586,Ursodeoxycholic acid
,24135887,C(max),"Compared with control rats, the mean area under concentration-time curve of baicalin was reduced from 13.25 ± 0.24 mg/L h to 7.62 ± 0.15 mg/L h and 4.97 ± 0.21 mg/L h, and the C(max) value was decreased from 1.31 ± 0.03 mg/L to 0.62 ± 0.05 mg/L and 0.36 ± 0.04 mg/L in rats pretreated with ursodeoxycholic acid at doses of 75 mg/kg and 150 mg/kg, respectively, for six consecutive days.",Ursodeoxycholic acid pretreatment reduces oral bioavailability of the multiple drug resistance-associated protein 2 substrate baicalin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24135887/),[mg] / [l],1.31,129661,DB01586,Ursodeoxycholic acid
,24135887,C(max),"Compared with control rats, the mean area under concentration-time curve of baicalin was reduced from 13.25 ± 0.24 mg/L h to 7.62 ± 0.15 mg/L h and 4.97 ± 0.21 mg/L h, and the C(max) value was decreased from 1.31 ± 0.03 mg/L to 0.62 ± 0.05 mg/L and 0.36 ± 0.04 mg/L in rats pretreated with ursodeoxycholic acid at doses of 75 mg/kg and 150 mg/kg, respectively, for six consecutive days.",Ursodeoxycholic acid pretreatment reduces oral bioavailability of the multiple drug resistance-associated protein 2 substrate baicalin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24135887/),[mg] / [l],0.62,129662,DB01586,Ursodeoxycholic acid
,24135887,C(max),"Compared with control rats, the mean area under concentration-time curve of baicalin was reduced from 13.25 ± 0.24 mg/L h to 7.62 ± 0.15 mg/L h and 4.97 ± 0.21 mg/L h, and the C(max) value was decreased from 1.31 ± 0.03 mg/L to 0.62 ± 0.05 mg/L and 0.36 ± 0.04 mg/L in rats pretreated with ursodeoxycholic acid at doses of 75 mg/kg and 150 mg/kg, respectively, for six consecutive days.",Ursodeoxycholic acid pretreatment reduces oral bioavailability of the multiple drug resistance-associated protein 2 substrate baicalin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24135887/),[mg] / [l],0.36,129663,DB01586,Ursodeoxycholic acid
,15289960,maximum serum concentration,"The profile for serum EE2 concentration was similar during UDCA (mean maximum serum concentration 177 pg/ml, SEM 59) and during placebo treatment (153 pg/ml, SEM 62), and mean area under the curve (AUC) was 1374 pg/h per ml (SEM 580) and 1320 pg/h per ml (SEM 551) during the two regimens, respectively.",Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289960/),[pg] / [ml],177,131153,DB01586,Ursodeoxycholic acid
,15289960,maximum serum concentration,"The profile for serum EE2 concentration was similar during UDCA (mean maximum serum concentration 177 pg/ml, SEM 59) and during placebo treatment (153 pg/ml, SEM 62), and mean area under the curve (AUC) was 1374 pg/h per ml (SEM 580) and 1320 pg/h per ml (SEM 551) during the two regimens, respectively.",Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289960/),[pg] / [ml],153,131154,DB01586,Ursodeoxycholic acid
,15289960,area under the curve (AUC),"The profile for serum EE2 concentration was similar during UDCA (mean maximum serum concentration 177 pg/ml, SEM 59) and during placebo treatment (153 pg/ml, SEM 62), and mean area under the curve (AUC) was 1374 pg/h per ml (SEM 580) and 1320 pg/h per ml (SEM 551) during the two regimens, respectively.",Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289960/),[pg] / [h·ml],1374,131155,DB01586,Ursodeoxycholic acid
,15289960,area under the curve (AUC),"The profile for serum EE2 concentration was similar during UDCA (mean maximum serum concentration 177 pg/ml, SEM 59) and during placebo treatment (153 pg/ml, SEM 62), and mean area under the curve (AUC) was 1374 pg/h per ml (SEM 580) and 1320 pg/h per ml (SEM 551) during the two regimens, respectively.",Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289960/),[pg] / [h·ml],1320,131156,DB01586,Ursodeoxycholic acid
,15289960,serum enrichment,"During UDCA treatment, serum enrichment with this bile acid and with the metabolite iso-UDCA was 29% (16%) and 3% (2%), respectively.",Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289960/),%,29,131157,DB01586,Ursodeoxycholic acid
,15289960,serum enrichment,"During UDCA treatment, serum enrichment with this bile acid and with the metabolite iso-UDCA was 29% (16%) and 3% (2%), respectively.",Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289960/),%,3,131158,DB01586,Ursodeoxycholic acid
,8060468,tmax,Median tmax did not change significantly after UDCA (3.0 vs 4.0 h without UDCA) and only 7 of 12 patients (58%) showed a rise in the amount of cyclosporin absorbed over 24 h with the AUC not having changed significantly (median 4527 vs 4979 micrograms.h.l-1 without UDCA).,Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),h,3.0,138639,DB01586,Ursodeoxycholic acid
,8060468,tmax,Median tmax did not change significantly after UDCA (3.0 vs 4.0 h without UDCA) and only 7 of 12 patients (58%) showed a rise in the amount of cyclosporin absorbed over 24 h with the AUC not having changed significantly (median 4527 vs 4979 micrograms.h.l-1 without UDCA).,Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),h,4.0,138640,DB01586,Ursodeoxycholic acid
,8060468,AUC,Median tmax did not change significantly after UDCA (3.0 vs 4.0 h without UDCA) and only 7 of 12 patients (58%) showed a rise in the amount of cyclosporin absorbed over 24 h with the AUC not having changed significantly (median 4527 vs 4979 micrograms.h.l-1 without UDCA).,Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),[h·μg] / [l],4527,138641,DB01586,Ursodeoxycholic acid
,8060468,AUC,Median tmax did not change significantly after UDCA (3.0 vs 4.0 h without UDCA) and only 7 of 12 patients (58%) showed a rise in the amount of cyclosporin absorbed over 24 h with the AUC not having changed significantly (median 4527 vs 4979 micrograms.h.l-1 without UDCA).,Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),[h·μg] / [l],4979,138642,DB01586,Ursodeoxycholic acid
,8060468,Cmax,"Median Cmax and C24 also increased only marginally following UDCA administration (616 vs 587 micrograms.l-1 and 87 vs 58 micrograms.l-1 without UDCA, respectively).",Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),[μg] / [l],616,138643,DB01586,Ursodeoxycholic acid
,8060468,Cmax,"Median Cmax and C24 also increased only marginally following UDCA administration (616 vs 587 micrograms.l-1 and 87 vs 58 micrograms.l-1 without UDCA, respectively).",Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),[μg] / [l],587,138644,DB01586,Ursodeoxycholic acid
,8060468,C24,"Median Cmax and C24 also increased only marginally following UDCA administration (616 vs 587 micrograms.l-1 and 87 vs 58 micrograms.l-1 without UDCA, respectively).",Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),[μg] / [l],87,138645,DB01586,Ursodeoxycholic acid
,8060468,C24,"Median Cmax and C24 also increased only marginally following UDCA administration (616 vs 587 micrograms.l-1 and 87 vs 58 micrograms.l-1 without UDCA, respectively).",Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),[μg] / [l],58,138646,DB01586,Ursodeoxycholic acid
,8060468,AUC,"In the cholestatic patients, median AUC was 50% smaller (3223 vs 6439 micrograms.",Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),μg,3223,138647,DB01586,Ursodeoxycholic acid
,8060468,AUC,"In the cholestatic patients, median AUC was 50% smaller (3223 vs 6439 micrograms.",Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),μg,6439,138648,DB01586,Ursodeoxycholic acid
,8060468,t1/2 a,h.l-1) and median t1/2 a was 100% longer (1.58 vs 0.8 h) than in patients without cholestasis.,Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),h,1.58,138649,DB01586,Ursodeoxycholic acid
,8060468,t1/2 a,h.l-1) and median t1/2 a was 100% longer (1.58 vs 0.8 h) than in patients without cholestasis.,Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),h,0.8,138650,DB01586,Ursodeoxycholic acid
,10971229,AUC,"The mean AUC was 68.99 micromol/1.6 h-1 for the USA UDCA tablet, 59.34 micromol/1.6 h-1 for the Canadian UDCA tablet, 55.55 micromol/1.6 h-1 for Ursolvan capsules, and 46.66 micromol/1.6 h-1 for Actigall capsules.",Bioavailability of four ursodeoxycholic acid preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971229/),[μM] / [1.6·h],68.99,140047,DB01586,Ursodeoxycholic acid
,10971229,AUC,"The mean AUC was 68.99 micromol/1.6 h-1 for the USA UDCA tablet, 59.34 micromol/1.6 h-1 for the Canadian UDCA tablet, 55.55 micromol/1.6 h-1 for Ursolvan capsules, and 46.66 micromol/1.6 h-1 for Actigall capsules.",Bioavailability of four ursodeoxycholic acid preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971229/),[μM] / [1.6·h],59.34,140048,DB01586,Ursodeoxycholic acid
,10971229,AUC,"The mean AUC was 68.99 micromol/1.6 h-1 for the USA UDCA tablet, 59.34 micromol/1.6 h-1 for the Canadian UDCA tablet, 55.55 micromol/1.6 h-1 for Ursolvan capsules, and 46.66 micromol/1.6 h-1 for Actigall capsules.",Bioavailability of four ursodeoxycholic acid preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971229/),[μM] / [1.6·h],55.55,140049,DB01586,Ursodeoxycholic acid
,10971229,AUC,"The mean AUC was 68.99 micromol/1.6 h-1 for the USA UDCA tablet, 59.34 micromol/1.6 h-1 for the Canadian UDCA tablet, 55.55 micromol/1.6 h-1 for Ursolvan capsules, and 46.66 micromol/1.6 h-1 for Actigall capsules.",Bioavailability of four ursodeoxycholic acid preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971229/),[μM] / [1.6·h],46.66,140050,DB01586,Ursodeoxycholic acid
,10971229,Cmax,"The mean Cmax values were 24.29, 17.85, 16.63 and 413.32 nmol/mL, respectively.",Bioavailability of four ursodeoxycholic acid preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971229/),[nM] / [ml],24.29,140051,DB01586,Ursodeoxycholic acid
,10971229,Cmax,"The mean Cmax values were 24.29, 17.85, 16.63 and 413.32 nmol/mL, respectively.",Bioavailability of four ursodeoxycholic acid preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971229/),[nM] / [ml],17.85,140052,DB01586,Ursodeoxycholic acid
,10971229,Cmax,"The mean Cmax values were 24.29, 17.85, 16.63 and 413.32 nmol/mL, respectively.",Bioavailability of four ursodeoxycholic acid preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971229/),[nM] / [ml],16.63,140053,DB01586,Ursodeoxycholic acid
,10971229,Cmax,"The mean Cmax values were 24.29, 17.85, 16.63 and 413.32 nmol/mL, respectively.",Bioavailability of four ursodeoxycholic acid preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971229/),[nM] / [ml],413.32,140054,DB01586,Ursodeoxycholic acid
,10971229,Tmax,"The mean Tmax was 1.82, 2.3, 2.79 and 3.39 h, respectively.",Bioavailability of four ursodeoxycholic acid preparations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971229/),h,1.82,140055,DB01586,Ursodeoxycholic acid
,10971229,Tmax,"The mean Tmax was 1.82, 2.3, 2.79 and 3.39 h, respectively.",Bioavailability of four ursodeoxycholic acid preparations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971229/),h,2.3,140056,DB01586,Ursodeoxycholic acid
,10971229,Tmax,"The mean Tmax was 1.82, 2.3, 2.79 and 3.39 h, respectively.",Bioavailability of four ursodeoxycholic acid preparations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971229/),h,2.79,140057,DB01586,Ursodeoxycholic acid
,10971229,Tmax,"The mean Tmax was 1.82, 2.3, 2.79 and 3.39 h, respectively.",Bioavailability of four ursodeoxycholic acid preparations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971229/),h,3.39,140058,DB01586,Ursodeoxycholic acid
,26382575,AUC0-24 h,"The mean systemic exposure of UDCA was higher in the five subjects with one copy of the FXR -1G>T variant allele than in those homozygous for the wild-type allele (n = 21) (AUC0-24 h : 38.5 ± 28.2 vs. 20.9 ± 8.0 μg h/mL, P = 0.021), but this difference appeared mainly due to one outlier with the -1GT genotype and elevated baseline and post-treatment UDCA concentrations.",Effect of common polymorphisms of the farnesoid X receptor and bile acid transporters on the pharmacokinetics of ursodeoxycholic acid. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26382575/),[h·μg] / [ml],38.5,142837,DB01586,Ursodeoxycholic acid
,26382575,AUC0-24 h,"The mean systemic exposure of UDCA was higher in the five subjects with one copy of the FXR -1G>T variant allele than in those homozygous for the wild-type allele (n = 21) (AUC0-24 h : 38.5 ± 28.2 vs. 20.9 ± 8.0 μg h/mL, P = 0.021), but this difference appeared mainly due to one outlier with the -1GT genotype and elevated baseline and post-treatment UDCA concentrations.",Effect of common polymorphisms of the farnesoid X receptor and bile acid transporters on the pharmacokinetics of ursodeoxycholic acid. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26382575/),[h·μg] / [ml],20.9,142838,DB01586,Ursodeoxycholic acid
,28236406,flow rate,"Chromatographic separation was performed on an Agilent Zorbax SB-C18 column (3.5 μm, 100 mm × 2.1 mm), with acetonitrile and 0.1% aqueous formic acid as mobile phase at a flow rate of 0.3 mL·min-1.",LC-MS/MS analysis and pharmacokinetic study on five bioactive constituents of Tanreqing injection in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28236406/),[ml] / [min],0.3,152895,DB01586,Ursodeoxycholic acid
greater,28236406,extraction recoveries,"The extraction recoveries were greater than 71% and accuracy (relative recovery) was from 89% to 137% for all analytes, except endogenous bile acids.",LC-MS/MS analysis and pharmacokinetic study on five bioactive constituents of Tanreqing injection in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28236406/),%,71,152896,DB01586,Ursodeoxycholic acid
,28236406,relative recovery),"The extraction recoveries were greater than 71% and accuracy (relative recovery) was from 89% to 137% for all analytes, except endogenous bile acids.",LC-MS/MS analysis and pharmacokinetic study on five bioactive constituents of Tanreqing injection in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28236406/),%,89,152897,DB01586,Ursodeoxycholic acid
,28236406,relative recovery),"The extraction recoveries were greater than 71% and accuracy (relative recovery) was from 89% to 137% for all analytes, except endogenous bile acids.",LC-MS/MS analysis and pharmacokinetic study on five bioactive constituents of Tanreqing injection in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28236406/),%,137,152898,DB01586,Ursodeoxycholic acid
,23634754,diameter,"The mean diameter, polydispersity index and entrapment efficiency of UA-SME were 251.9 nm, 0.241 and 74.36%, respectively.",Combination of submicroemulsion and phospholipid complex for novel delivery of ursodeoxycholic acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23634754/),nm,251.9,157448,DB01586,Ursodeoxycholic acid
,23634754,polydispersity index,"The mean diameter, polydispersity index and entrapment efficiency of UA-SME were 251.9 nm, 0.241 and 74.36%, respectively.",Combination of submicroemulsion and phospholipid complex for novel delivery of ursodeoxycholic acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23634754/),%,0.241,157449,DB01586,Ursodeoxycholic acid
,23634754,entrapment efficiency,"The mean diameter, polydispersity index and entrapment efficiency of UA-SME were 251.9 nm, 0.241 and 74.36%, respectively.",Combination of submicroemulsion and phospholipid complex for novel delivery of ursodeoxycholic acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23634754/),%,74.36,157450,DB01586,Ursodeoxycholic acid
,23634754,Tmax,"Pharmacokinetic parameters of UA and UA-SME in rats were Tmax 2.215 and 1.489 h, Cmax 0.0364 and 0.1562 μg/mL, AUC0-∞ 3.682 and 13.756 μg h/mL, respectively.",Combination of submicroemulsion and phospholipid complex for novel delivery of ursodeoxycholic acid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23634754/),h,2.215,157451,DB01586,Ursodeoxycholic acid
,23634754,Tmax,"Pharmacokinetic parameters of UA and UA-SME in rats were Tmax 2.215 and 1.489 h, Cmax 0.0364 and 0.1562 μg/mL, AUC0-∞ 3.682 and 13.756 μg h/mL, respectively.",Combination of submicroemulsion and phospholipid complex for novel delivery of ursodeoxycholic acid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23634754/),h,1.489,157452,DB01586,Ursodeoxycholic acid
,23634754,Cmax,"Pharmacokinetic parameters of UA and UA-SME in rats were Tmax 2.215 and 1.489 h, Cmax 0.0364 and 0.1562 μg/mL, AUC0-∞ 3.682 and 13.756 μg h/mL, respectively.",Combination of submicroemulsion and phospholipid complex for novel delivery of ursodeoxycholic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23634754/),[μg] / [ml],0.0364,157453,DB01586,Ursodeoxycholic acid
,23634754,Cmax,"Pharmacokinetic parameters of UA and UA-SME in rats were Tmax 2.215 and 1.489 h, Cmax 0.0364 and 0.1562 μg/mL, AUC0-∞ 3.682 and 13.756 μg h/mL, respectively.",Combination of submicroemulsion and phospholipid complex for novel delivery of ursodeoxycholic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23634754/),[μg] / [ml],0.1562,157454,DB01586,Ursodeoxycholic acid
,23634754,AUC0-∞,"Pharmacokinetic parameters of UA and UA-SME in rats were Tmax 2.215 and 1.489 h, Cmax 0.0364 and 0.1562 μg/mL, AUC0-∞ 3.682 and 13.756 μg h/mL, respectively.",Combination of submicroemulsion and phospholipid complex for novel delivery of ursodeoxycholic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23634754/),[h·μg] / [ml],3.682,157455,DB01586,Ursodeoxycholic acid
,23634754,AUC0-∞,"Pharmacokinetic parameters of UA and UA-SME in rats were Tmax 2.215 and 1.489 h, Cmax 0.0364 and 0.1562 μg/mL, AUC0-∞ 3.682 and 13.756 μg h/mL, respectively.",Combination of submicroemulsion and phospholipid complex for novel delivery of ursodeoxycholic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23634754/),[h·μg] / [ml],13.756,157456,DB01586,Ursodeoxycholic acid
,7596954,area under the curve [AUC,"The area under the curve [AUC, mumol l-1 (8 h)] following oral administration of enteric-coated, sinking UDCA (39.0 +/- 8.5) was significantly higher than that obtained after both conventional UDCA (30.5 +/- 4.9) and floating enteric coated UDCA (29.3 +/- 3.4).","Bioavailability study of a new, sinking, enteric-coated ursodeoxycholic acid formulation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596954/),[8·h·μM] / [l],39.0,185842,DB01586,Ursodeoxycholic acid
,7596954,area under the curve [AUC,"The area under the curve [AUC, mumol l-1 (8 h)] following oral administration of enteric-coated, sinking UDCA (39.0 +/- 8.5) was significantly higher than that obtained after both conventional UDCA (30.5 +/- 4.9) and floating enteric coated UDCA (29.3 +/- 3.4).","Bioavailability study of a new, sinking, enteric-coated ursodeoxycholic acid formulation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596954/),[8·h·μM] / [l],30.5,185843,DB01586,Ursodeoxycholic acid
,7596954,area under the curve [AUC,"The area under the curve [AUC, mumol l-1 (8 h)] following oral administration of enteric-coated, sinking UDCA (39.0 +/- 8.5) was significantly higher than that obtained after both conventional UDCA (30.5 +/- 4.9) and floating enteric coated UDCA (29.3 +/- 3.4).","Bioavailability study of a new, sinking, enteric-coated ursodeoxycholic acid formulation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596954/),[8·h·μM] / [l],29.3,185844,DB01586,Ursodeoxycholic acid
,29032305,f2,"In spite of the fact that dissolution time profiles of 250mg ursodeoxycholic acid (UCDA) capsules developed by Sponsor and 250mg hard capsules produced by Ursofalk®, Dr. Falk Pharma GmbH, indicated similarity (f2=60.6), a bioavailability study indicated unexpected differences in the formulations.",Physicochemical pharmacokinetics as an optimization tool for generic development: A case study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29032305/),,60.6,186995,DB01586,Ursodeoxycholic acid
,16288302,time to progression,"Median time to progression was 19 weeks (95% CI, 15-22 weeks), and median survival was 52 weeks (95% CI, 39-64 weeks).",A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16288302/),weeks,19,188256,DB01586,Ursodeoxycholic acid
,16288302,survival,"Median time to progression was 19 weeks (95% CI, 15-22 weeks), and median survival was 52 weeks (95% CI, 39-64 weeks).",A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16288302/),weeks,52,188257,DB01586,Ursodeoxycholic acid
,27377011,t1/2,The N(4)-ursodeoxycholic acid conjugate of cytarabine (compound 5) exhibited optimal stability (t1/2=90min) in vitro and a 3.9-fold prolonged half-life of cytarabine in vivo.,Transporter-targeted cholic acid-cytarabine conjugates for improved oral absorption. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27377011/),min,90,219066,DB01586,Ursodeoxycholic acid
,25138679,maximum plasma concentration (C(max)),"In the UDCA phase, the maximum plasma concentration (C(max)) of pitavastatin was slightly higher than in the control phase (48.6 ± 22.9 ng/mL vs. 42.4 ± 16.1 ng/mL).","Ursodeoxycholic acid, an inhibitor of hepatocyte nuclear factor 1α, did not increase the systemic exposure of pitavastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25138679/),[ng] / [ml],48.6,222161,DB01586,Ursodeoxycholic acid
,25138679,maximum plasma concentration (C(max)),"In the UDCA phase, the maximum plasma concentration (C(max)) of pitavastatin was slightly higher than in the control phase (48.6 ± 22.9 ng/mL vs. 42.4 ± 16.1 ng/mL).","Ursodeoxycholic acid, an inhibitor of hepatocyte nuclear factor 1α, did not increase the systemic exposure of pitavastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25138679/),[ng] / [ml],42.4,222162,DB01586,Ursodeoxycholic acid
,12830002,peak plasma concentrations,Patients with PBC stage IV showed significantly higher peak plasma concentrations (4.9 +/- 3.5 vs.,Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830002/),,4.9,238429,DB01586,Ursodeoxycholic acid
,12830002,areas under the plasma concentration-time curves (AUC),1.5 +/- 0.4 ng/mL; P <.05) and areas under the plasma concentration-time curves (AUC) (23.2 +/- 16.8 vs.,Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830002/),,23.2,238430,DB01586,Ursodeoxycholic acid
,12830002,AUC,"Equally, AUC of budesonide were significantly increased under a multiple dose regimen on day 21 (14.0 +/- 11.6 vs.",Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830002/),,14.0,238431,DB01586,Ursodeoxycholic acid
,1876573,excretion,Faecal UDCA excretion was 15-20% while the urinary extraction was 1.5% during 24 h.,Pharmacokinetics of ursodeoxycholic acid in rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1876573/),%,15-20,242596,DB01586,Ursodeoxycholic acid
,1876573,urinary extraction,Faecal UDCA excretion was 15-20% while the urinary extraction was 1.5% during 24 h.,Pharmacokinetics of ursodeoxycholic acid in rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1876573/),%,1.5,242597,DB01586,Ursodeoxycholic acid
,15726657,AUC,"Metabolite formation was enhanced by rifampicin, but not by UDCA (e.g., AUC(16alpha-hydroxyprednisolone)/AUC(budesonide) in patients: baseline, 8.6 +/- 3.9; UDCA, 10.7 +/- 7.1; rifampicin, 527.0 +/- 248.7).",No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726657/),,8.6,253862,DB01586,Ursodeoxycholic acid
,15726657,AUC,"Metabolite formation was enhanced by rifampicin, but not by UDCA (e.g., AUC(16alpha-hydroxyprednisolone)/AUC(budesonide) in patients: baseline, 8.6 +/- 3.9; UDCA, 10.7 +/- 7.1; rifampicin, 527.0 +/- 248.7).",No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726657/),,10.7,253863,DB01586,Ursodeoxycholic acid
,15726657,AUC,"Metabolite formation was enhanced by rifampicin, but not by UDCA (e.g., AUC(16alpha-hydroxyprednisolone)/AUC(budesonide) in patients: baseline, 8.6 +/- 3.9; UDCA, 10.7 +/- 7.1; rifampicin, 527.0 +/- 248.7).",No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726657/),,527.0,253864,DB01586,Ursodeoxycholic acid
